Padcev-Keytruda sets new standard in bladder cancer as Seagen and Astellas move toward full approval: #ESMO23 - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
MADRID — Thousands of ESMO delegates on Sunday gave a standing ovation to confirmatory trial data showing Seagen and Astellas Pharma’s Padcev in combination with Merck’s Keytruda is the “new standard of care” in first-line bladder cancer. Data from the study …